image
Amicus Therapeutics, Inc. FOLD
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 6.875
8.07 %
$ 2.12 B
Market Cap
-56.92
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Aug, 5, 2025.

The intrinsic value of one FOLD stock under the worst case scenario is HIDDEN Compared to the current market price of 6.88 USD, Amicus Therapeutics, Inc. is HIDDEN

FOLD Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Aug, 5, 2025.

The intrinsic value of one FOLD stock under the base case scenario is HIDDEN Compared to the current market price of 6.88 USD, Amicus Therapeutics, Inc. is HIDDEN

FOLD Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Aug, 5, 2025.

The intrinsic value of one FOLD stock under the best case scenario is HIDDEN Compared to the current market price of 6.88 USD, Amicus Therapeutics, Inc. is HIDDEN

FOLD Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart FOLD

image
1M 13%
6M -39%
1Y -45%
3Y -77%
5Y -124%
All
$10.0$10.0$9.5$9.5$9.0$9.0$8.5$8.5$8.0$8.0$7.5$7.5$7.0$7.0$6.5$6.5$6.0$6.0$5.5$5.515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 JulAug '25Aug '25
FINANCIALS
528 M REVENUE
32.29%
Growth Rates
1Year 32.29%
3Years 20.03%
5Years 23.72%
7Years 46.24%
10Years 83.45%
24.9 M OPERATING INCOME
133.85%
Growth Rates
1Year 133.85%
3Years 28.55%
5Years 15.80%
7Years 10.85%
10Years 8.98%
-56.1 M NET INCOME
62.99%
Growth Rates
1Year 62.99%
3Years 39.27%
5Years 30.91%
7Years 20.68%
10Years 2.04%
-33.9 M OPERATING CASH FLOW
50.95%
Growth Rates
1Year 50.95%
3Years 44.89%
5Years 32.97%
7Years 23.22%
10Years 4.13%
-560 K INVESTING CASH FLOW
-0.57%
Growth Rates
1Year -0.57%
3Years -0.24%
5Years -0.12%
7Years 55.85%
10Years 40.86%
5.12 M FINANCING CASH FLOW
-91.70%
Growth Rates
1Year -91.70%
3Years -71.10%
5Years -52.75%
7Years -42.53%
10Years -28.12%
155 M REVENUE
23.50%
Growth Rates
1Year 32.29%
3Years 20.03%
5Years 23.72%
7Years 46.24%
10Years 83.45%
-9.47 M OPERATING INCOME
-19.14%
Growth Rates
1Year 133.85%
3Years 28.55%
5Years 15.80%
7Years 10.85%
10Years 8.98%
-21.7 M NET INCOME
-147.13%
Growth Rates
1Year 62.99%
3Years 39.27%
5Years 30.91%
7Years 20.68%
10Years 2.04%
7.76 M OPERATING CASH FLOW
298.11%
Growth Rates
1Year 50.95%
3Years 44.89%
5Years 32.97%
7Years 23.22%
10Years 4.13%
-32.9 M INVESTING CASH FLOW
-61.15%
Growth Rates
1Year -0.57%
3Years -0.24%
5Years -0.12%
7Years 55.85%
10Years 40.86%
-11.7 M FINANCING CASH FLOW
-1066.55%
Growth Rates
1Year -91.70%
3Years -71.10%
5Years -52.75%
7Years -42.53%
10Years -28.12%
Balance Sheet Amicus Therapeutics, Inc.
image
Current Assets 505 M
Cash & Short-Term Investments 250 M
Receivables 101 M
Other Current Assets 154 M
Non-Current Assets 280 M
Long-Term Investments 0
PP&E 51.7 M
Other Non-Current Assets 229 M
31.84 %12.88 %19.58 %6.58 %29.12 %Total Assets$785.0m
Current Liabilities 149 M
Accounts Payable 12.9 M
Short-Term Debt 8.46 M
Other Current Liabilities 127 M
Non-Current Liabilities 442 M
Long-Term Debt 435 M
Other Non-Current Liabilities 7.1 M
21.54 %73.64 %Total Liabilities$591.0m
EFFICIENCY
Earnings Waterfall Amicus Therapeutics, Inc.
image
Revenue 528 M
Cost Of Revenue 52.9 M
Gross Profit 475 M
Operating Expenses 433 M
Operating Income 24.9 M
Other Expenses 81 M
Net Income -56.1 M
600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)528m(53m)475m(433m)25m(81m)(56m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
89.98% GROSS MARGIN
89.98%
Averages
1Year 89.98%
3Years 89.64%
5Years 89.15%
7Years 88.27%
10Years 78.42%
4.71% OPERATING MARGIN
4.71%
Averages
1Year 4.71%
3Years -25.26%
5Years -46.94%
7Years -108.58%
10Years -562.55%
-10.62% NET MARGIN
-10.62%
Averages
1Year -10.62%
3Years -40.14%
5Years -61.71%
7Years -126.65%
10Years -569.03%
-28.91% ROE
-28.91%
Averages
1Year -28.91%
3Years -105.27%
5Years -98.79%
7Years -95.79%
10Years -84.46%
-7.15% ROA
-7.15%
Averages
1Year -7.15%
3Years -19.77%
5Years -23.64%
7Years -29.19%
10Years -28.34%
7.53% ROIC
7.53%
Averages
1Year 7.53%
3Years -12.55%
5Years -19.28%
7Years -26.29%
10Years -26.92%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Amicus Therapeutics, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -56.1 M
Depreciation & Amortization 8.55 M
Capital Expenditures -3.55 M
Stock-Based Compensation 84.9 M
Change in Working Capital 0
Others -60.5 M
Free Cash Flow -37.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Amicus Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for FOLD of $16 , with forecasts ranging from a low of $13 to a high of $20 .
FOLD Lowest Price Target Wall Street Target
13 USD 89.09%
FOLD Average Price Target Wall Street Target
16 USD 132.73%
FOLD Highest Price Target Wall Street Target
20 USD 190.91%
Price
Max Price Target
Min Price Target
Average Price Target
202018181616141412121010886644Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Amicus Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
4 K USD 1
6-9 MONTHS
260 K USD 1
9-12 MONTHS
245 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Amicus (FOLD) Q2 Revenue Jumps 22% Amicus (FOLD) Q2 Revenue Jumps 22% fool.com - 4 days ago
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200 Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA, targeting $1 billion in revenue by 2028. The DMX-200 licensing deal opens a major market opportunity in FSGS, with positive interim phase 3 data and potential for broader rare renal indications. Financially, Amicus has limited cash but can raise more through its ATM facility, and its approved drugs are generating double-digit sales growth. seekingalpha.com - 4 days ago
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda. zacks.com - 4 days ago
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.06 per share a year ago. zacks.com - 5 days ago
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold ® Q2 Revenue of $128.9M, up 12% at CER Pombiliti ® + Opfolda ® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J. globenewswire.com - 5 days ago
In NCLA Amicus Win, Eleventh Circuit Vacates SEC Order Used to Fund Its Illegal Collection of Data American Securities Association and Citadel Securities LLC v. U.S. Securities and Exchange Commission American Securities Association and Citadel Securities LLC v. U.S. Securities and Exchange Commission globenewswire.com - 1 week ago
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 1 week ago
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m. globenewswire.com - 2 weeks ago
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm PHILADELPHIA , July 10, 2025 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) ("Amicus") on behalf of the company's shareholders.  Year to date, shares of Amicus' stock have declined over 32% in value, to trade at a current price of less than $7.00 per share. prnewswire.com - 3 weeks ago
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of adult patients with late-onset Pompe disease (LOPD). globenewswire.com - 1 month ago
U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association globenewswire.com - 1 month ago
The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy Physician group filed an amicus brief in Chiles v. Salazar defending the right of licensed therapists to offer "conversion therapy" in gender dysphoria. globenewswire.com - 1 month ago
8. Profile Summary

Amicus Therapeutics, Inc. FOLD

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 2.12 B
Dividend Yield 0.00%
Description Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Contact 3675 Market Street, Philadelphia, PA, 19104 https://amicusrx.com
IPO Date May 31, 2007
Employees 499
Officers Mr. Bradley L. Campbell M.B.A. Chief Executive Officer, President & Director Ms. Diana Moore Head of Global Corporate Communications Mr. Simon Nicolas Reade Harford Chief Financial Officer Mr. David M. Clark Chief People Officer Ms. Samantha L. Prout Chief Accounting Officer & Controller Ms. Ellen S. Rosenberg J.D. Chief Legal Officer & Corporate Secretary Mr. Andrew Faughnan Vice President of Investor Relations Dr. Jill Weimer Ph.D. Chief Science Officer Dr. Jeffrey P. Castelli Ph.D. Chief Development Officer Mr. Patrik S. Florencio Esq. Global Chief Compliance & Risk Officer